{
    "root": "466f1f42-ccce-4467-9289-838ae470442e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "bupropion Hydrochloride",
    "value": "20250502",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POTASSIUM CHLORIDE",
            "code": "660YQ98I10"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": "bupropion hydrochloride tablets aminoketone antidepressant , indicated treatment major depressive disorder ( mdd ) . ( 1 )",
    "contraindications": "starting dose : 200 mg/day given 100 mg twice daily . ( 2.1 ) general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) 3 days , may increase dose 300 mg/day , given 100 mg 3 times daily interval least 6 hours doses . ( 2.1 ) usual target dose : 300 mg/day 100 mg 3 times daily . ( 2.1 ) maximum dose : 450 mg/day given 150 mg 3 times daily . ( 2.1 ) periodically reassess dose need maintenance treatment . ( 2.1 ) moderate severe hepatic impairment : 75 mg daily . ( 2.2 , 8.7 ) mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.2 , 8.7 ) renal impairment : consider reducing dose and/or frequency . ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride tablets usp , 75 mg available round , yellow colored tablets , debossed `` 191 `` one side plain side . supplied follows : blistercards 30 : ndc 0615-8261-39 bupropion hydrochloride tablets usp , 100 mg available round , red colored tablets , debossed `` 192 `` one side plain side . tablets protected light moisture stored 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) . [ usp controlled room temperature . ] dispense tight , light-resistant container defined usp using child-resistant closure . keep container tightly closed . protect light moisture .",
    "adverseReactions": "seizure disorder . ( 4 , 5.3 ) current prior diagnosis bulimia anorexia nervosa . ( 4 , 5.3 ) abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs . ( 4 , 5.3 ) monoamine oxidase inhibitors ( maois ) : maois intended treat psychiatric disorders bupropion hydrochloride tablets within 14 days stopping treatment bupropion hydrochloride tablets . bupropion hydrochloride tablets within 14 days stopping maoi intended treat psychiatric disorders . addition , start bupropion hydrochloride tablets patient treated linezolid intravenous methylene blue . ( 4 , 7.6 ) known hypersensitivity bupropion ingredients bupropion hydrochloride tablets . ( 4 , 5.8 )",
    "indications_original": "Bupropion hydrochloride tablets are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD). ( 1 )",
    "contraindications_original": "Starting dose: 200 mg/day given as 100 mg twice daily. ( 2.1 ) General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) After 3 days, may increase the dose to 300 mg/day, given as 100 mg 3 times daily at an interval of at least 6 hours between doses. ( 2.1 ) Usual target dose: 300 mg/day as 100 mg 3 times daily. ( 2.1 ) Maximum dose: 450 mg/day given as 150 mg 3 times daily. ( 2.1 ) Periodically reassess the dose and need for maintenance treatment. ( 2.1 ) Moderate to severe hepatic impairment: 75 mg once daily. ( 2.2 , 8.7 ) Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion Hydrochloride Tablets USP, 75 mg are available as round, yellow colored tablets, debossed \"191\" on one side and plain on other side. They are supplied as follows:\n                  Blistercards of 30: NDC 0615-8261-39\n                  Bupropion Hydrochloride Tablets USP, 100 mg are available as round, red colored tablets, debossed \"192\" on one side and plain on other side. \n                  The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]\n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed. Protect from light and moisture.",
    "adverseReactions_original": "Seizure disorder. ( 4 , 5.3 ) Current or prior diagnosis of bulimia or anorexia nervosa.      ( 4 , 5.3 ) Abrupt discontinuation of alcohol, benzodiazepines,      barbiturates, antiepileptic drugs. ( 4 , 5.3 ) Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs      intended to treat psychiatric disorders with bupropion hydrochloride      tablets or within 14 days of stopping treatment with bupropion      hydrochloride tablets. Do not use bupropion hydrochloride tablets within      14 days of stopping an MAOI intended to treat psychiatric disorders. In      addition, do not start bupropion hydrochloride tablets in a patient who is      being treated with linezolid or intravenous methylene blue.      ( 4 , 7.6 ) Known hypersensitivity to bupropion or other ingredients of      bupropion hydrochloride tablets. ( 4 , 5.8 )"
}